Nat. Rev. Rheumatol. doi: /nrrheum

Slides:

Advertisements

Similar presentations

Nat. Rev. Rheumatol. doi: /nrrheum

Advertisements

Figure 1 Lymphocytes during the disease

Figure 2 Cell-mediated disease mechanisms of lupus nephritis

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Connexins in cartilage

Figure 5 Involvement of B cells in SLE

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Figure 1 Radiation-induced effects on tumour cells

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Factors underlying metabolic alterations in osteoarthritis

Figure 1 Induction of immune tolerance

Figure 2 Main functions of IL-1

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Engineering regulatory T cells against factor VIII inhibitors

Figure 3 The T-cell cytokine tree in IBD

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Targeted versus untargeted metabolomics approaches

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Figure 3 Simplified EULAR and GRAPPA

Figure 2 Simplified EULAR and GRAPPA

Figure 3 Transcriptome studies performed in the target

Figure 2 Shared genetic loci in systemic autoimmune diseases

Antigen-induced regulatory T cells

Figure 3 TNFSF activities enhancing immune cell activation

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 4 Combination immunotherapeutic approaches with imatinib

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Approaches to targeting inhibitory immune receptors

Figure 1 Overview of the immunopathogenesis of ulcerative colitis

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Cas9 targeting using crRNA (CRISPR

Figure 2 Interaction effects between heterozygous HLA‑DRB1

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Statistical approaches for the analysis of metabolomic data

Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.

Figure 3 Cell-surface markers for NP cell differentiation

Figure 5 The role of Ly6Chi and Ly6Clo monocytes

Figure 3 Multi-hit model for autoimmune diseases

Figure 1 Simplified EULAR and GRAPPA

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

during the alloimmune response

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Autoimmunity through Cytokine-Induced Dendritic Cell Activation

Volume 32, Issue 4, Pages (April 2010)

Figure 1 Biospecimen handling pipeline

Figure 2 Logistical requirements for autologous

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Principles for the diagnosis and management of osteoarthritis

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Figure 1 Chronic inflammation and DNA damage in people with SLE

Figure 3 Nuclear-penetrating autoantibodies and synthetic lethality

Figure 2 Cellular contributions to the development of SLE

Figure 2 Phenotypes of osteoarthritis

Figure 1 Differential effects of bone-forming agents on bone surfaces

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Underlying mechanisms of TREG cells in atherosclerosis

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 The role of macrophages in RA

Figure 2 The main effects of adipokines on bone remodelling in osteoarthritis Figure 2 | The main effects of adipokines on bone remodelling in osteoarthritis.

Meet the Ikaros Family IL-2 Helios CD103 GITR Naïve CD4+ T cell

Volume 32, Issue 4, Pages (April 2010)

Model of the accumulation of Treg cells in human tumors.

Figure 2 Involvement of plasmacytoid dendritic cells

Presentation transcript:

Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.107 Figure 4 Strategies for utilizing dendritic cells to target autoreactive T cells Figure 4 | Strategies for utilizing dendritic cells to target autoreactive T cells. Autologous tolerogenic dendritic cells (tolDCs) can be generated from autologous monocytes loaded with autoantigens or by tolerizing DCs using nanoparticles coupled to tolerogenic autoepitope peptides. These cells induce differentiation and expansion of regulatory T (Treg) cells. Alternatively, engineered plasmid DNA encoding the autoantigen can be injected intramuscularly into patients; after uptake by tolDCs, the autoepitopes are presented to autoreactive T cells, resulting in T cell suppression and/or differentiation into Treg cells Pozsgay, J. et al. (2017) Antigen-specific immunotherapies in rheumatic diseases Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.107